邹游 陈始明 张雷波 陶泽璋.非索非那定治疗变应性鼻炎的随机对照试验的Meta分析[J].现代生物医学进展英文版,2014,14(24):4672-4677. |
非索非那定治疗变应性鼻炎的随机对照试验的Meta分析 |
The Treatment of Fexofenadine for Allergic Rhinitis:a Meta-analysisof Randomized Controlled Trials |
|
DOI: |
中文关键词: 变应性鼻炎 非索非那定 随机对照实验 Meta 分析 |
英文关键词: Allergic rhinitis Fexofenadine Randomized controlled trials Meta-analysis |
基金项目:国家自然科学基金项目(81070766) |
|
Hits: 736 |
Download times: 0 |
中文摘要: |
目的:评价非索非那定治疗变应性鼻炎的疗效及其安全性。方法:计算机检索SCI,Pubmed,Elsevier,Cochrane 图书馆,知网,
万方数据库,维普数据库中关于非索非那定治疗变应性鼻炎的随机对照试验,同时追索纳入文献的参考文献。检索年限均从建库
检索到2013 年12 月。由两名评价员独立筛查文献,对纳入的文献进行质量评价并提取文献,对符合质量标准的随机对照试验
(RCT)进行Meta 分析,比较非索非那定组和安慰剂组鼻部症状评分、血清中白三烯浓度、生活质量评价、症状改善率和安全性评
估。统计学分析采用RevMan5.2 软件。结果:共纳入9 个RCT。患者口服非索非那定片30 mg/d,120 mg/d,180 mg/d 后可有效改善
变应性鼻炎患者的症状,可降低患者鼻部症状评分、血清中白三烯浓度;有效提高生活质量,降低患者总的生活质量评分(P均<0.05)。非
索非那定不良反应的发生率与安慰剂组相似,不良反应发生率差异无统计学意义(P>0.05)。结论:患者口服非索非那定片30
mg/d, 120 mg/d, 180 mg/d 后可以有效缓解患者的症状,改善患者的生活质量,且不良反应发生率与对照组相近。基于非索非那定
较好的有效性和安全性,故可以广泛应用于临床,更加有效的缓解变应性鼻炎患者的症状。 |
英文摘要: |
Objective:To evaluate the therapeutic effect and safety of fexofenadine in patients with allergic rhinitis.Methods:SCI,
Pubmed,Elsevier, Cochrane library datebases, CNKI, Wanfang Data, VIP had been searched for the the Randomized controlled trials
(RCTs) of the treatment of fexofenadine for allergic rhinitis from the date of establishment of the datebases to December 2013. The
bibliographies of the included studies were searched too. Two independent reseachers evaluated the included studies revised edition of
the scale and extracted dates. The randomized controlled trials(RCTs) which conformed to the quality standard would be resorted to Meta
analysis. The study had been analyzed several aspects including the nasal symptom scores, the concentration of serum leukotriene, the
quality of life, symptom improvement rate, safety between the fexofenadine group and the placebo group. The RevMan 5.2 was used to
statistical analysis.Results:A total of 9 trials were included. After the patients oral fexofenadine 30 mg/d, 120 mg/d, 180 mg/d,
fexofenadine was valid to improve the symptom and the quality of life in the allergic rhinitis patients. The nasal symptom scores, the
concentration of serum leukotriene, the quality of life, symptom improvement rate in group treated with fexofenadine showed
significantly difference (P<0.05) when compared with controls. The side effects incidence in the fexofenadinee (P>0.05) in two groups.Conclusion:After the patients oral fexofenadine 30 mg/d, 120 mg/d, 180 mg/d, fexofenadine can efficiently release the symptom and
improve the quality of life. The side effects incidence is very similar to the controls. The fexofenadine that has better efficacy and safety.
In order to improve the symptom, they can be widely used in clinical application. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|